About KCNMA1-linked Channelopathy
A rare genetic disorder affecting the BK channel — a protein critical to how the brain and muscles communicate. Here is what we know, and what researchers are working to learn.
What is KCNMA1-linked Channelopathy?
KCNMA1-linked Channelopathy is caused by mutations in the KCNMA1 gene, which encodes the alpha subunit of the BK (Big Potassium) channel. This channel plays a fundamental role in regulating electrical activity in neurons, muscle cells, and other tissues throughout the body. When the gene is mutated, the channel may become overactive (gain-of-function) or underactive (loss-of-function), disrupting normal cellular signaling.
Because the BK channel is expressed in many tissues — including the brain, heart, and smooth muscle — the effects of KCNMA1 mutations can vary widely from person to person. No two cases are exactly alike, which makes diagnosis and treatment particularly challenging.
Two Types of Mutations
Gain-of-function (GOF)
The BK channel becomes overactive, allowing too much potassium to flow. This is most commonly associated with paroxysmal non-epileptic events, movement disorders, and dyskinesia.
Loss-of-function (LOF)
The BK channel becomes underactive or absent. This is more commonly associated with epilepsy, intellectual disability, and developmental delay.
Signs and Symptoms
Symptoms vary significantly depending on the type of mutation and the individual. Common features reported across the KCNMA1 community include:
Neurological
- Epilepsy or seizure-like episodes
- Paroxysmal non-epileptic events (PNEE)
- Intellectual disability or developmental delay
- Hypotonia (low muscle tone)
Movement
- Dyskinesia (involuntary movements)
- Ataxia (coordination difficulties)
- Dystonia
- Delayed motor milestones
Other features
- Speech and language delays
- Feeding difficulties in infancy
- Behavioral challenges
- Sleep disturbances
This list is not exhaustive. Symptoms vary widely between individuals. Always consult a qualified medical professional for diagnosis and treatment guidance.
Genetics and Inheritance
KCNMA1 mutations can occur de novo (new mutations not inherited from either parent) or can be inherited in an autosomal dominant pattern, meaning one copy of the altered gene is sufficient to cause the disorder. Genetic testing — typically through whole exome sequencing or targeted gene panels — is the primary method of diagnosis.
Because the condition is so rare and was only formally described in 2015, many individuals may remain undiagnosed or misdiagnosed for years. If you suspect KCNMA1 Channelopathy, ask your neurologist or geneticist about comprehensive genetic testing.
Getting a Diagnosis
Clinical evaluation
A neurologist or clinical geneticist reviews symptoms, medical history, and family history.
Genetic testing
Whole exome sequencing or a channelopathy gene panel can identify KCNMA1 variants. Testing may be recommended for parents as well.
Variant interpretation
A clinical geneticist or molecular pathologist classifies the variant (pathogenic, likely pathogenic, variant of uncertain significance).
Multidisciplinary care
Management typically involves neurology, genetics, physical therapy, occupational therapy, speech therapy, and other specialists depending on the individual's needs.
Science & discovery
Current Research
KCNMA1-linked Channelopathy is an active area of research. Scientists are working to understand the precise mechanisms by which different mutations affect BK channel function, and how those changes translate into the wide spectrum of clinical presentations seen in patients.
BK channel pharmacology
Researchers are investigating existing and novel compounds that can modulate BK channel activity — potentially offering targeted treatments for gain-of-function or loss-of-function variants.
Natural history studies
Collecting longitudinal data from patients worldwide to better understand disease progression, outcomes, and the full range of symptoms.
Patient registries
International registries are being established to connect researchers with patients and families, accelerating the path to clinical trials.
Have questions about a diagnosis?
Our community includes families, patients, and medical professionals who have navigated this journey. You don't have to figure it out alone.